Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura  by Ruggenenti, Piero et al.
Kidney International, Vol. 60 (2001), pp. 831–846
PERSPECTIVES IN BASIC SCIENCE
Thrombotic microangiopathy, hemolytic uremic syndrome, and
thrombotic thrombocytopenic purpura
PIERO RUGGENENTI, MARINA NORIS, and GIUSEPPE REMUZZI
Mario Negri Institute for Pharmacological Research and Unit of Nephrology and Dialysis, Ospedali Riuniti di Bergamo, Italy
Thrombotic microangiopathy, hemolytic uremic syndrome, and the consequent organ dysfunction. Depending on whether
thrombotic thrombocytopenic purpura. The term thrombotic renal or brain lesions prevail, two pathologically indistin-
microangiopathy (TMA) defines a lesion of vessel wall thick- guishable, but somehow clinically different entities haveening (mainly arterioles or capillaries), intraluminal platelet
been described. They have been uniformly termed in thethrombosis, and partial or complete obstruction of the vessel
last few decades as hemolytic uremic syndrome (HUS),lumina. Depending on whether renal or brain lesions prevail,
two pathologically indistinguishable but somehow clinically dif- after the five children with hemolytic anemia, thrombo-
ferent entities have been described: the hemolytic uremic syn- cytopenia, and acute renal failure reported by Gasser et
drome (HUS) and the thrombotic thrombocytopenic purpura
al in 1955 [3], or as thrombotic thrombocytopenic pur-(TTP). Injury to the endothelial cell is the central and likely
pura (TTP), after the case of a 16-year-old female withinciting factor in the sequence of events leading to TMA. Loss
of physiological thromboresistance, leukocyte adhesion to dam- acute febrile pleiochromic anemia, petechiae, paralysis,
aged endothelium, complement consumption, abnormal von and coma reported by Moschowitz in 1923 [4]. The for-
Willebrand factor release and fragmentation, and increased mer syndrome usually affects young children; the latter
vascular shear stress may then sustain and amplify the microan-
occurs in adults. In the only comparative analysis of adultgiopathic process. Intrinsic abnormalities of the complement
forms of HUS or TTP available so far, hematologicalsystem and of the von Willebrand factor pathway may account
for a genetic predisposition to the disease that may play a para- and neurological abnormalities at disease onset were indis-
mount role in particular in familial and recurrent forms. Out- tinguishable [5, 6]. Moreover, regardless of the severity
come is usually good in childhood, Shiga toxin-associated HUS, of renal involvement, adults have similar outcomes thatwhereas renal and neurological sequelae are more frequently
mostly depend on when treatment with plasma is effectivereported in adult, atypical, and familial forms of HUS and in
TTP. Plasma infusion or exchange is the only treatment of in normalizing laboratory signs and inducing remission
proven efficacy. Bilateral nephrectomy and splenectomy may of clinical symptoms [5, 6]. To be practical and avoid
serve as rescue therapies in very selected cases of plasma resis- confusion, here we first discuss children with HUS initi-
tant HUS or recurrent TTP, respectively.
ated by infections with Shiga toxin (Stx)-producing strains
of Shigella or Escherichia coli infection (Stx-associated
HUS). This form of HUS of children is separated fromThe term thrombotic microangiopathy (TMA), first
all the other forms of children HUS and from HUS andintroduced by Symmers in 1952 [1], defines a lesion of
TTP of adults because the outcome and response tovessel wall thickening (mainly arterioles or capillaries)
therapy is different in Stx-associated childhood HUS aswith swelling or detachment of the endothelial cell from
compared with all the other forms of HUS and TTP [7].the basement membrane, accumulation of fluffy material
As well, simply for practical reasons, for all forms ofin the subendothelial space, intraluminal platelet throm-
non-Stx–associated HUS or TTP, the broader term HUS/bosis, and partial or complete obstruction of the vessel
TTP [8] will be used.lumina [2]. This lesion is common to various diseases
[reviewed in 2]. Laboratory features of thrombocyto-
penia and hemolytic anemia are almost invariably pres- ROLE OF ENDOTHELIAL INJURY:
ent in patients with TMA lesions, and reflect consump- AN OLD IDEA STILL IN PLACE
tion and disruption of platelets and erythrocytes in the
Most authorities consider endothelial injury as the cen-microvasculature. Additional clinical signs depend on
tral and likely inciting factor that sustains the microangio-the diverse distribution of the microvascular lesions and
pathic process (Fig. 1). This is not a recent idea, however.
As early as in 1942, Mark Altschule of Harvard Medical
Key words: Shigatoxin, endothelial activation, von Willebrand factor. School suggested that microvascular endothelial activa-
tion was the primary event causing platelet deposition 2001 by the International Society of Nephrology
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Fig. 1. A suggested sequence of events leading to thrombotic microangiopathy in predisposed individuals exposed to triggers of vascular injury. Genetic
predisposition may have a predominant role in familial and recurrent forms, exposition to triggers of vascular injury in Shiga toxin E. coli-associated
HUS.
in arterioles and capillaries with secondary “clearance mice [12]. These findings were taken to indicate that a
toxin possibly released by the microorganism could in-of enormous numbers of platelets from the circulation”
[9]. Actually, of the agents that have been associated duce hemorrhagic necrosis of the gastrointestinal mucosa
and—once absorbed into the blood stream—of otherwith the disease in subsequent years, all are toxic to
microvascular endothelium [reviewed in 2]. Moreover, organs. Several years later, Konowalciuck, Speirs and
Stavric noted that E. coli isolated from human cases withplasma from patients with acute HUS/TTP induces apo-
ptosis of human endothelial cells from the renal and diarrhea, produced a toxin similar to the one of Shigella
cerebral microvasculature, but not from large vessels [10]. dysenteriae type 1 (Shiga toxin or Stx) found cytopathic
to Vero cells (African green monkey kidney cells) [13].
This toxin was subsequently given different names such
AGENTS IMPLICATED IN ENDOTHELIAL
as Shiga-like toxin (SLT), or verotoxin. In 1978, Koster
ACTIVATION AND DAMAGE
et al suggested that a circulating toxin was the cause of
Shiga toxins colitis, hemolysis, and renal failure in children HUS with
evidence of S. dysenteriae type 1 infection [14]. A fewDespite that, the term HUS was introduced in 1954
[3]. A careful look at the older literature reveals some years later, a case-control study by Riley et al found a
strong association between hemorrhagic colitis and inges-relevant observations. In 1927, Adam first reported that
an infant epidemiology of gastroenteritis was associated tion of E. coli O157:H7-infected beef patties at outlets of
a well-known fast-food restaurant chain [15]. Recoverywith a special type of bacterium coli, biochemically unique
for its fermentation properties [11]. Subsequent observa- of the same strain of E. coli (which could be readily distin-
guished from other fecal E. coli because of its uniquetions described a similar disease with diarrhea, occasion-
ally complicated by purpura, anuria, and neurological signs, inability to ferment sorbitol) from the stools of about half
the 47 children with diarrhea, but from none of the healthythat was characterized at autopsy by capillary and arteriolar
thrombosis and glomerular tuft occlusion by fibrin thrombi. controls, suggested a cause-and-effect relationship between
food-borne E. coli infection and hemorrhagic colitis [15].E. coli serotype O111:B4 was considered the causative
agent in more than 90% of these cases [12]. Further studies During the same period, Karmali et al demonstrated an
increased Stx activity in fecal filtrates and increased Stx-found a filterable agent isolated from the stools of these
children that caused diarrhea in calves and was lethal to neutralizing antibody titer in sera from children with
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E. coli O157:H7 infection and sporadic, diarrhea-associ- never been detected in the circulation of patients with
HUS. Of note, a very recent study found that, in vitro, Stxated HUS [16]. Thus, almost 60 years after the seminal
rapidly binds to polymorphonuclear leukocytes (PMNs),observations by Adams et al, these findings provided
but not to erythrocytes, monocytes, platelets, or lipopro-definitive demonstration of a direct role of a bacterial
teins [24]. However, the Stx receptor on PMNs has atoxin (Stx) in the pathogenesis of HUS.
100-fold lower affinity than the high-affinity receptorThus far, more than 100 E. coli serotypes have been
(globotriaosylceramide or Gb3) expressed on glomerularfound to produce Stx, but only few of them have been
endothelial cells. As a consequence, at least in the in vitroinvolved in human disease. The serotype O157:H7 is by
cocultures, PMNs loaded with Stx transfer the ligand tofar the most common pathogen in the United States and
glomerular endothelial cells, which promote cell deathEurope, but other strains, particularly the O111:H-sero-
[24]. Should this occur in vivo, it would explain the rapidtype, are frequently reported in other areas of the world
clearance of Stx from the circulation and its release to[17]. Of interest, E. coli O157:H7 strains that are isolated
target organs where the toxin exerts its cytopathic effect.from patients with HUS usually produce both Stx-1 and
Shiga toxins produced by S. dysenteriae type 1 and E.Stx-2 or only Stx-2. Of note, in a recent epidemy of Stx-1
coli comprise a family of multisubunit toxins that are struc-E. coli hemorrhagic colitis, no patient developed HUS,
turally and genetically related. Shiga-like toxins (SLTs)suggesting that Stx-2 E. coli is the involved pathogen at
are classified according to the extent of antigenic similar-least in most of the cases (abstract; Hashimoto H, et al,
ity to Shiga toxin. SLTs whose cytotoxic activity is neu-Pediatrics 103:141, 1999) [18].
tralized by antisera to Shiga toxin are referred to as typeEscherichia coli O157:H7 colonizes healthy cattle in-
1 (Stx-1), whereas SLTs that are not cross-neutralizedtestine, but also has been isolated from deer, sheep, goats,
by anti–Shiga-toxin antibodies are classified as type 2horses, dogs, birds, and flies [19]. It is found in manure,
(Stx-2). Subtypes of Shiga-toxin 2 (Stx-2c and Stx-2e)water troughs, and other places in farms, which may
share cross-hybridization of their genes under conditionsexplain the increased risk of infection observed in people
of high stringency, but show significant differences inliving in rural areas. The microorganism is transmitted
biologic activity, serological reactivity, or receptor bind-to humans by food and water, directly from person to
ing [25]. All members of the toxin family consist of pen-person [20, 21] and occasionally through occupational
tamers of 7 to 8 kD binding subunits (B subunits) inexposure. Most food-borne outbreaks have been attrib-
noncovalent association with single enzymatic subunitsuted to cattle-derived foods, in particular beef and raw
(A subunits) of approximately 35 kD. They bind to targetmilk, although contaminated foods from other sources,
cells via the neutral glycolipid Gb3 and globotetraosyl-such as lamb and jerky, have been involved in some cases.
ceramide (Gb4) and mediate protein synthesis inhibitionMeat probably becomes contaminated at the time of in target cells by the specific N-glycosidase activity of A
slaughter, and internalization of the microorganism dur- subunits that act at a site adjacent to adenine-4324 in
ing grinding may render it more likely to survive cooking. the 28 S rRNA component of eukaryotic ribosomes.
Fruits and vegetables may also be contaminated, and Human glomerular endothelial cells are sensitive to the
radish sprouts, lettuce, apple cider, unpasteurized apple cytotoxic effects of Stx, particularly when exposure to
juice, and alfalfa sprouts have been implicated in several tumor necrosis factor- (TNF-) increases Gb3 expres-
outbreaks. Water-borne outbreaks have occurred as a sion on cell surface and Gb3-mediated toxin binding and
result of drinking and swimming in unchlorinated water. internalization by endocytosis [26]. Gb3 fatty acid compo-
Person-to-person transmission has been reported in day- sition and phospholipid chain length within the phospho-
care and chronic-care facilities [reviewed in 17]. lipid bilayer also may play an important role in the intra-
After oral ingestion of contaminated food or water, cellular distribution and biological effects of the toxin.
E. coli O157:H7 reaches the gut and closely adheres to For instance, Gb3 receptors containing shorter chain fatty
the epithelial cells of the gastrointestinal mucosa. Adhe- acid species direct the toxin to the endoplasmic reticu-
sion by a 97 kD outer membrane protein, intimin, pro- lum/rather than to the Golgi apparatus, and increase Stx
duces characteristic “attaching and effacing” lesions aimed cytotoxicity [27]. Genetic differences in Gb3 fatty acid
at preventing the expulsion of the microorganism [22]. composition might therefore account for different indi-
The consequent disruption of the brush border per se is vidual susceptibility to the effects of Stx [27]. Inhibition
sufficient to produce nonbloody diarrhea. In addition, of protein synthesis and cell death are the usual effects
however, E. coli O157:H7 (as well as other Stx-producing of Stx. Sublethal Stx doses also may alter the production of
serotypes such as E. coli O111, nonmotile O26:H11, or endothelial-derived vasoactive mediators such as endo-
O103:H2) may produce large amounts of Stx, which tra- thelin and nitric oxide, which, in turn, might contribute to
verse polarized gastrointestinal epithelial cells, probably the microvascular changes characteristic of hemorrhagic
via transcellular pathways [23], and gains the systemic colitis and HUS. Moreover, sublethally injured endothe-
circulation. How the toxin is transferred from the intes- lial cells have an increased susceptibility to injury medi-
ated by activated PMNs [28]. Studies have shown thattine to target organs is still not known. Free toxin has
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up-regulation of cytokine production, PMN activation, Bacterial neuraminidases
and enhanced oxidant injury potentiate the direct cyto- Following a few reports in the European literature,
pathic effects of Stx; this amplifies vascular damage and, Klein et al found Thomsen-Friedenreich antigen on eryth-
conceivably, alters the normal thromboresistant pheno- rocytes and in the glomeruli of two one-year-old children
type of the endothelial cell [reviewed in 29]. who died from HUS secondary to pneumococcus pneu-
However, endothelial cells are not the only targets for monia and sepsis [35]. Binding studies also found weak
Stx in the kidney, and several renal cell types (such as IgM deposits in the glomeruli indicative of a specific IgM
proximal and distal tubular cells or mesangial and epithe- binding to the Thomsen-Friedenreich antigen. Subsequent
lial glomerular cells) have receptors for Stx and are dam- studies demonstrated neuraminidase activity in organism-
aged by the toxin in vitro [30]. These findings suggest free filtrates of sera from three infants with Streptococcus
that renal injury in Stx-HUS, unlike other forms of HUS/ pneumoniae-associated HUS, but not in filtrates of sera
TTP, is not simply a consequence of vascular involve- from a large series of samples from children with Strepto-
ment in the microangiopathic process, but may reflect, at coccus pneumoniae infection and no evidence of HUS.
least in part, a primary damage to parenchymal cells [30]. Since the Thomsen-Friedenreich antigen is normally cov-
Experimental evidence indicates that sites of Gb3 ex- ered by N-acetyl neuraminic acid (sialic acid) moieties,
pression coincide with sites of Stx-induced tissue damage it has been speculated that Streptococcus pneumoniae-
[2]. Indeed, after a challenge with Stx-1 purified from E. derived neuraminidase, by removing sialic acid from the
coli O157:H7, rabbits presented neurologic and enteric cell membranes, exposes this cryptic antigen to preformed
features of endothelial swelling and luminal occlusion circulating IgM antibodies [35, 36]. Then, IgM binding
of small arteries and arterioles, but no signs of renal to Thomsen-Friedenreich antigen exposed on platelet and
involvement [31]. Binding studies identified Stx recep- endothelial cell surface would cause platelet aggregation
tors in the central nervous system and in the gastrointes- and endothelial damage [35, 36]. Binding of IgM antibod-
tinal tract, but not in the kidney [31]. In humans, the ies to the antigen expressed on circulating erythrocytes
Gb3 receptor is expressed not only in the kidney, but may explain why Coombs-positive hemolytic anemia is
also on the membrane of epithelial and endothelial cells so frequently reported in patients with neuraminidase-
of gastrointestinal mucosa and submucosa, respectively.
induced HUS.
Of interest, a recent study in baboons, which share with
humans a similar distribution of gastrointestinal and re- Immune complexes
nal Gb3 receptors, demonstrated that Stx injection in-
Complement-dependent antibodies, which are cyto-duces direct injury to the endothelial and epithelial cells
toxic endothelial cells, have been found in the serumof the gastrointestinal and renal microcirculation [32].
and plasma of patients with HUS/TTP [37]. ComplementIn this animal model, structural changes reminiscent of
and IgG and IgM antibodies can be found in kidney biop-the autoptic changes observed in children with HUS and
sies [2]. Together, these findings suggest a pathogeneticneurological involvement also were detected in the cen-
role for immune complexes. This possibility is consistenttral nervous system, despite a relatively low expression
with findings that endothelial cells exposed in vitro toof the Gb3 receptor in this organ [32]. Increased local
sera of patients with HUS/TTP in the presence of com-release of inflammatory mediators was advocated to con-
plement show ultrastructural changes of cytoplasmic in-tribute to renal tissue injury. This possibility is supported
clusions and cytoplasmic and nuclear degeneration sug-by the observation that neurological changes can be asso-
gestive of endothelial cell apoptosis [37].ciated with increased interleukin (IL)-6 concentration in
Hemolytic uremic syndrome/TTP complicates immuneliquor. Thus, the finding that, despite negligible Gb3 re-
diseases, in particular systemic lupus erythematosus, andceptor expression, adult humans may develop central ner-
increasingly is reported in association with the antiphos-vous system lesions secondary to Stx-producing E. coli
pholipid syndrome [reviewed in 38].infection [20, 33] could be due to a facilitating effect of
enhanced local release of inflammatory mediators [31, 32].
Drugs
Endotoxins Several chemotherapeutic agents, including mitomy-
cin C (MMC), cisplatin, daunorubimicin, cytosine arabi-Upon E. coli infection, bacterial-derived endotoxins
noside, chlorozotocin, neocarcinostatin, and deoxycofor-(lipopolysaccharides or LPS) and Stx act synergetically
mycin, have been implicated in a syndrome of thromboticin initiating damage to target organs, including the kid-
microangiopathy designated as chemotherapy-associ-ney. LPS prime the endothelial cells to undergo apopto-
ated HUS (C-HUS) [reviewed in 39]. MMC causes TMAsis when exposed to picomolar amounts of Stx. More-
after direct infusion into rat kidneys. Endothelial cellsover, LPS derived from Stx producing E. coli activate
metabolize MMC to a reactive intermediate that cross-PMNs to release TNF-, IL-1, elastase, and free radicals
that are highly toxic to microvascular endothelium [34]. links cellular DNA and proteins. Endothelial cells, ex-
Ruggenenti et al: TMA, HUS and TTP 835
posed to MMC in vitro at concentrations equivalent to CONSEQUENCES OF VASCULAR INJURY
therapeutic drug levels in vivo, survive but subsequently Virtually all properties of the normal microvascular
show both an impaired ability to divide and a reduced endothelium are altered in HUS/TTP. Endothelial cells
thrombin-stimulated production of prostacyclin. synthesize many substances involved in coagulation and
Cyclosporine. Cyclosporine A (CsA) has been associ- fibrinolysis, including prostacyclin, nitric oxide (NO),
ated with de novo thrombotic microangiopathy in renal vWF, thrombomodulin, tissue-type plasminogen activa-
and nonrenal transplantation and in patients with Beh- tor inhibitor and protein S. Loss of prostacyclin [47] and
c¸ets disease [40]. Thrombotic microangiopathy in renal increase in vWF [48] have been claimed to account for
allograft recipients is most common in the first weeks, the loss of physiologic thromboresistance and for the
when CsA drug levels are highest, and should be differ- consequent widespread platelet aggregation in vascular
entiated from both humorally and/or cell-mediated rejec- beds throughout the body, creating a cycle of vasocon-
tion. In renal allograft recipients, CsA enhances platelet striction with platelet and fibrin deposition and further
aggregation and thromboxane A2 production, and high thrombus formation.
CsA levels correlate with increased thrombomodulin
and von Willebrand factor serum levels. Since the first Leukocyte activation and complement consumption
report by Schmidt et al in 1991, more than 20 cases have The interaction between leukocytes and damaged en-
been described providing evidence that tacrolimus may dothelial cells is instrumental to the development of mi-
cause HUS/TTP [41, 42]. The disease is reported in 1 to crovascular injury in Stx-associated HUS, as documented
4.7% of tacrolimus treated patients. It is more frequently by experimental and clinical evidence [34]. Neutrophils
diagnosed in the first year after transplantation, although from children in the acute phase of HUS adhere to endo-
it may occur at any time. thelial cells in vitro more tightly than normal neutrophils
Ticlopidine and clopidogrel. Ticlopidine has been asso- and induce endothelial injury by degrading endothelial cell
ciated with the development of HUS/TTP, but this event fibronectin, possibly by the release of neutrophil-specific
is rare (1 in 1600 patients treated with ticlopidine after proteases [34]. Stx in vitro promotes massive leukocyte
cardiac stenting) [43]. Clopidogrel, a new antiplatelet
adhesion and transmigration to endothelium under flow
agent that has achieved widespread clinical acceptance
conditions by up-regulating endothelial expression of ad-
because of a more favorable safety profile than ticlopi-
hesive proteins and chemokines (abstract; Zoja et al,dine, also has been associated with the disease, and 11
J Am Soc Nephrol 10:595A, 1999). Platelet and leukocytecases have been reported recently [44]. Ten of these
activation concur to promote the formation of C3bBbpatients developed TTP within two weeks from begin-
convertase, which in turn leads to cleavage of the thirdning the drug treatment. Ticlopidine and clopidogrel are
fraction of complement (C3) to the active form C3b,structurally related derivatives of thienopyridine and act
ready to react with any cell surface or membrane nucleo-by blocking an adenosine diphosphate-binding site on
phile. Low C3 levels were first described in diarrhea-platelets, which inhibits the expression of the glycopro-
associated HUS in the early 1970s [49]. Persistently lowtein IIb/IIIa receptor in the high-affinity configuration
complement levels were found in different forms of HUSthat binds fibrinogen and large von Willebrand factor
[49]. Granular C3 deposits in glomeruli and arterioles of(vWF) multimers. Why these two drugs cause TTP is
patients with either diarrhea-associated or adult formsnot fully clear, but of great interest, as patients with
of HUS/TTP and evidence of C3 breakdown productsticlopidine- or clopidogrel-associated TTP have a defi-
in patients’ sera were taken to reflect complement con-ciency of vWF-cleaving protease activity in plasma that
sumption in the microvasculature [50].appears quite comparable to the deficiency observed in
idiopathic TTP [44].
Abnormal von Willebrand factorQuinine. Quinine is widely used for the prophylaxis
release and processingof nocturnal cramps, but is also present in tonic water and
In normal individuals, vWF is formed as large multi-bitter lemon drinks. Occasionally, it may cause hemolytic
mers [ultralarge (UL) multimers] due to the polymeriza-anemia, thrombocytopenia, disseminated intravascular
tion in endothelial cells and megakaryocytes of a nativecoagulation, and HUS [45]. HUS typically occurs in pa-
subunit with an apparent molecular mass of 225 kD, andtients presensitized by prior exposure to quinine and
is stored as such in Weibel-Palade bodies and plateletrapidly follows re-ingestion of the compound. Quinine-
granules. UL multimers do not normally circulate, sincedependent antibodies to red blood cells, granulocytes,
they are rapidly reduced into smaller multimers soonand the glycoprotein Ib/IX and IIb/IIIa on platelet sur-
after their secretion by cleavage at position 842 Tyr-843face have been involved in the pathogenesis of the dis-
Met of the mature subunit. A major contribution to theease. Renal failure is usually severe, but the outcome is
understanding of vWF processing was provided by Fur-good, provided that patients are treated early enough
with plasma exchange [46]. lan et al [51] and Tsai and Lia [52], who partially purified
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and characterized a plasma metalloprotease that physio- tease activity [59]. Of interest, in both patients with consti-
logically cleaves ultralarge vWF multimers. The prote- tutional protease deficiency, disease remission achieved
ase, of approximately 300 kD, needs bivalent cations for by plasma therapy was concurrent with an almost full
its activation, is inhibited by calcium-chelating agents, recovery of the vWF-cleaving protease activity. Both
and is activated only in conditions of low ionic strength patients achieved a long-lasting remission, although pro-
or high shear stress. In vivo evidence that proteolytic tease activity decreased to less than 20% over 20 days
cleavage is involved in the modification of plasma multi- after plasma therapy withdrawal.
mers after secretion has been provided by studies show- In nonfamilial cases, the protease deficiency appears
ing that circulating vWF multimers are heterogeneous to be a consequence of a specific autoantibody that devel-
oligomers of a native 225 kD subunit and of proteolytic ops transiently and tends to disappear during remission
fragments with apparent molecular masses of 189, 176, [51]. In a patient with recurrent episodes of TTP shown to
and 140 kD [53]. In patients with HUS and TTP, in con- have an acquired inhibitor of the vWF-cleaving protease
trast to healthy subjects, UL multimers similar to the [60], splenectomy, performed one year after the first TTP
ones stored in endothelial cells and platelets were occa- event, resulted in the disappearance of the autoantibody
sionally detected in plasma [54]. The presence in patients and normalization of the protease activity, platelet count,
with HUS/TTP of circulating UL multimers that in vitro and hemoglobin levels [60].
are capable of supporting platelet aggregation more effi- At variance with TTP, in the previously mentioned
ciently than normal multimers was evidence for their studies, no deficiency was found in patients with familial
pathogenic role in microvascular thrombi [55]. However, or sporadic forms of HUS [51], suggesting that the pres-
direct proof that this was indeed the case was never pro- ence or absence of this activity were enough to classify
vided. Interestingly, the opposite appears true in vivo, patients as having HUS or TTP, respectively. More recent
since the available evidence is against the possibility that data, however, indicate that low or zero protease activity
UL vWF multimers when present in the circulation can is not confined to TTP and can even be found in a number
even cause intravascular thrombosis. UL multimers have of diseases associated with an increased tendency to throm-
been found in fetuses and newborns, but disappear within bosis, such as inflammatory states, liver cirrhosis, major
the first months of life, indicating that physiologic cleav- surgery (Mannucci et al, personal communication, Work-
age of vWF is less efficient at birth and fully develops shop on vWF and TTP, Bethesda, July 31, 2000), and
later in life [56]. Moreover, in patients with a rare variant disseminated malignancies [7]. Another child who was
of von Willebrand disease, named “Vicenza,” UL vWF diagnosed as HUS/TTP, although he had renal failure
multimers were constantly found in the circulation; none- and no neurological symptoms, showed with zero vWF
theless, these patients never experienced thrombotic epi-
protease activity [61]. Our group has obtained similarsodes; rather, they suffered with bleeding tendency [57].
results of complete lack of protease in two cases of recur-In patients with HUS/TTP who recovered after a sin-
rent HUS (unpublished results). These data indicate thatgle episode, UL multimers were found almost exclusively
the issue is controversial and the distinction betweenin the acute phase but not in remission, suggesting a mas-
HUS and TTP is much more complicated than presentedsive release from storage sites of acutely injured endothe-
in the New England Journal of Medicine articles [51, 52]lial cells that possibly transiently overwhelmed the
and accompanying editorial [55].plasma proteolytic capacity [58]. In contrast, those cases
A constant finding in the acute phase of different formsthat had a tendency to recur had circulating UL multi-
of HUS/TTP is an increase of low molecular weight mul-mers either in the acute phase or consistently in the
timers and a decrease of high molecular weight multi-remission phase of the disease, which was initially taken
mers, which reflects an enhanced proteolytic fragmen-as evidence of a state of persistent endothelial perturba-
tation of the molecule [62, 63]. That vWF undergoestion [54]. The hypothesis that circulating UL vWF multi-
excessive fragmentation in the acute phase of these dis-mers may reflect a condition of endothelial perturbation
eases is remarkably consistent with previous findings ofhas been recently challenged by findings that circulating
a relative decrease in the native 225 kD vWF subunit,UL multimers in chronic relapsing TTP were associated
which only occurs in the acute phase, accompanied bywith a reduced or totally absent activity of the above
a relative increase of fragments that can only derive fromvWF-cleaving protease activity that normally cleaves vWF
the cleavage of the native subunit [64].multimers to smaller molecular forms. In two large stud-
ies, vWF-cleaving protease deficiency was described in
Enhanced vascular shear stress as a determinant ofpatients with different forms of TTP [51, 52]. In familial
abnormal von Willebrand factor fragmentationforms of TTP, the deficiency is probably inherited as an
von Willebrand factor’s susceptibility to fragmentationautosomal recessive trait. Consistent with this possibility,
increases in response to rising levels of shear stress [65],complete deficiency of vWF-cleaving protease activity
which induces protein unfolding and makes vWF proteo-was found in two brothers with chronic relapsing TTP,
whereas their parents had approximately half-normal pro- lytic cleavage sites more accessible to specific plasma
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protease(s). It is speculated that enhanced shear stress of acute disease, and only two had moderately increased
LDH levels [67].in the severely narrowed damaged microvessels accounts
for the abnormal vWF fragmentation observed during Actually, low C3 levels are well known to accompany
the acute phases either of diarrhea-associated or idio-the acute phase of HUS/TTP. Evidence of increased
capacity of fragmented vWF to bind receptors on acti- pathic HUS [49] and likely reflect C3 consumption in
the microvasculature. Granular C3 deposits in glomerulivated platelets suggests that shear stress-induced vWF
fragmentation may contribute to maintain and further and arterioles of HUS patients [50] and evidence of C3
breakdown products in HUS sera [49] further documentspread microvascular thrombosis. In severe forms of
HUS that are resistant to plasma therapy, removal of the activation of the complement system in the acute
phase of the disease. Enhanced release of complementthe kidneys—a major site of vascular bed occlusion and
augmented shear stress—was followed by hematologic cleavage products (including C3a and C5a) consequent
to uncontrolled complement activation may contributeand clinical remission associated with restoring the vWF
fragmentation pathway to normal [62]. Consistent with to the microangiopathic process by stimulating neutro-
phil activation phagocytic adhesion to vascular endothe-this possibility in patients with recurrent and sporadic
HUS/TTP, increased vWF fragmentation normalized lium, or platelet aggregation, and by directly injuring the
endothelium through enhanced production of the mem-after resolution of the microangiophatic process.
brane attack complex, the final multimolecular unit of
the complement C5b-9.
GENETIC PREDISPOSITION
Two complement pathways can generate C3-activating
Congenital complement abnormalities enzymes: the classic convertase generated by the sequen-
tial reaction of C1, C4, and C2, and the alternative path-Over the last 20 years, approximately 140 cases of
familial HUS and TTP have been described in 70 fami- way convertase. Activation of classic and alternative
complement pathway—possibly triggered by circulatinglies, with the predominant features of HUS in two thirds
of the patients. Both autosomal-recessive and autosomal- immune complexes and damaged erythrocytes, respec-
dominant modes of inheritance have been recognized [66]. tively—is well documented in acute HUS [68], but consis-
Precipitating events such as pregnancy, virus-like dis- tently subsides with remission of the disease. In contrast,
ease, or sepsis have been reported only in a minority of in cases of familial HUS/TTP, serum C3 levels were consis-
cases. Evidence that some of these cases responded, at tently and remarkably depressed in cases as compared
least transiently, to plasma infusion or exchange, sug- with controls, even during remission of the disease [67].
gests that the genetic defect(s) associated with familial Even more interestingly, low C3 levels also were found
HUS/TTP were the cause of one or more abnormalities in the patients’ relatives, who had never suffered with
in plasma component(s) essential to the integrity of mi- HUS or TTP in the past and had no sign of the disease
crovascular circulation and/or to the defense mechanism at the time of the study [67]. Furthermore, either in cases
of the host endothelium against injurious agents. Thus, or in case-relatives depressed C3 values did not parallel
reduced serum levels of the third component (C3) of the similar changes in C4 levels. These data definitely ruled
complement system have been reported since 1974 [49] out the possibility that classic pathway activation ac-
in both the sporadic and familial forms of HUS [67]. That counted for hypocomplementemia in this series [67]. An
the disease may be related to an inherited congenital inherited defect in C3 synthesis has been suggested to
abnormality is consistent with the finding that more than account for decreased C3 serum concentration [67], but
50% of patients with familial HUS/TTP—as compared much more convincing data are now available that low
with only 10 to 20% in nonfamilial forms—had repeated C3 in HUS may derive from either a lack or altered function
recurrences. This genetical abnormality is likely to in- of factor H, a regulatory protein that inhibits the comple-
volve the complement system, as suggested by levels of ment activation through the alternative pathway [69].
circulating C3, which were extremely low in a large series
of familial cases as compared with controls [67]. Reduced
INHERITED FACTOR H DEFICIENCYC3 levels in cases and case relatives, but not in controls
In one patient with HUS and in his healthy brother,and the controls’ relatives, further indicate that the de-
a persistent reduction in C3 levels was found with veryfect clusters in families. Evidence that a low C3 concen-
low levels of factor H [70]. Finding that the parents, whotration was strongly associated with the disease even
were first cousins, had half-normal levels of factor H,more convincingly suggests the possibility of a tight (pos-
convincingly indicated that the defect was inherited. Asibly causal) relationship between decreased C3 and dis-
similar finding was later reported in another family. Inease manifestation [67]. On the other hand, in the pre-
a recent report, the association between inherited factorviously mentioned series, low C3 levels could not depend
H deficiency and low C3 levels was investigated in aon consumption in a still-ongoing microangiopathic pro-
cess, since no patient at the time of the study had any sign large series of families with a history of HUS/TTP [67].
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By radial immunodiffusion and Western blot analysis, a C to G transversion causing an arginine to glycine change
two affected subjects of one family were identified who in the short consensus repeat 20 (SCR20) [72]. This muta-
had very low circulating factor H levels, and moderately tion is likely to alter structure and hence function of
low levels were found in two healthy relatives. In these factor H protein without modifying its circulating levels.
patients, the cofactor activity of factor H, measured as The same authors also described a nonsense mutation,
the capacity to degrade C3b, was also reduced. In the located in SCR1 of factor H gene, in a single case with
other families, serum factor H concentration was normal late onset [72]. In a large series of patients, four new
[67]; however, normal serum levels do not necessarily heterozygous mutations in factor H gene were found
exclude an underlying biochemical abnormality in circu- [73]. Three of the mutations were observed in families
lating factor H. In this regard, in another family the with dominant transmission, the fourth was found in a
two affected members, and the healthy father, who had single case who experienced disease recurrence on the
normal serum concentrations of factor H by radial immu- renal allograft. Loirat et al have recently reported five
nodiffusion, Western blots showed additional bands of cases of atypical HUS with neonatal onset and 2 to 15
higher molecular weights that were not found in any relapses over 2 to 14 years follow-up, who had complete
controls [67]. The bands might represent dimeric forms and persistent vWF-cleaving protease deficiency (abstract;
of factor H. At variance, no differences were found in Loirat et al, Twelfth Congress of the International Pedi-
serum levels and patterns of FHL-1 and FHR proteins atric Nephrology Association, Seattle, WA, USA, Sep-
[69]. Similar results were obtained in another series of tember 1–2, 2001) [74, 75]. Another study reported an
patients with HUS [71]. apparent mutation in factor H (a C to T transition in
Factor H has several biological activities. It prevents SCR 20) in a family with HUS with a recessive mode of
the formation of C3bBb complex and accelerates the inheritance and severely depressed factor H levels [76].
dissociation of Bb from the C3 convertase. It acts as a However, two independent groups subsequently pro-
cofactor for factor I that degrades C3b [69], and it also vided evidence that the apparent mutation was actually
distinguishes between activator and nonactivator sur- an artifact caused by coamplification of a factor H-related
faces [69]. Other less well-defined functions of factor H gene, and demonstrated that the real mutation in this
have been suggested by the presence of at least two family is an A to T transversion and a 24 bp deletion
heparin binding sites in factor H protein that could facili- that was present in homozygosity in affected members
tate interaction with extracellular matrix [69]. An inter- patients and in heterozygosity in the healthy carriers
current exposure to agents potentially toxic to the vascu- (abstract; Caprioli et al, J Am Soc Nephrol 11:404A,
lar endothelium (such as certain virus, bacteria, toxins, 2000) [77]. Altogether, the available data provide com-
immunocomplexes, and cytotoxic drugs [2]) may initiate pelling molecular evidence that genetic alterations in fac-
a local intravascular thrombosis, which promotes C3bBb tor H are involved in both autosomal dominant and reces-
convertase formation and complement deposition within sive HUS. Data that followed exposure to SLT producing
capillary vessels. In normal conditions, however, by mod- E. coli, where only 2 to 7% of the patients progressed
ulating C3bBb activity factor H may effectively limit to overt HUS, suggest that a genetic predisposition also
complement deposition and further extension of the pro- may have a role in the typical diarrhea-associated forms.
cess [69]. In contrast, when the bioavailability and/or Polymorphisms in the promoter and in the coding regions
activity of factor H is congenitally defective, C3bBb con- of the factor H gene have been recently described. It is
vertase formation and complement deposition may be- intriguing to speculate that some of these polymorphic
come uncontrolled, with further extension of the micro- variants confer a genetic predisposition to SLT-induced
angiopathic process up to full manifestation of the disease. HUS. Although it seems clear that familial HUS is re-
lated to an inherited congenital defect, the cause of the
GENE MUTATIONS ACCOUNTING FOR syndrome is probably multifactorial and the inherited
FACTOR H DEFICIENCY OR ABNORMALITIES complement defects simply may represent a predisposing
condition that increases the risk of the disease in combi-The consistent association found in families between
nation to other intercurrent environmental or acquiredfactor H abnormalities and low C3 levels supports the
factors. Thus, in a family with hereditary hypocomplem-hypothesis that low C3 in the setting of familial HUS/
entemia, only one of the six members with low C3 levelsTTP may depend on a genetic deficiency of factor H.
developed HUS, apparently following a flu-like episodeA recent report on three large families with HUS
[67]. It is also possible that genetic defects in other com-documented that an area on chromosome 1q, where fac-
plement regulatory proteins (DAF, CR1, CR2, C4bp)tor H is mapped, segregates with HUS [72]. All subjects
might have a role in determining low C3 in familial HUSin the three families had normal serum factor H levels.
and TTP. Data support this possibility that the aboveHowever, affected members and obligate carriers within
genes map on the same region of chromosome 1q asone family were found, by mutation analysis, to have a
heterozygous point mutation in factor H, consisting of factor H [78].
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CLINICAL FEATURES OF THE DIFFERENT 80 mL/min as compared with 15 of 35 (42.8%) of those
with anuria duration 16 days [82]. The extent of acuteFORMS OF THROMBOTIC MICROANGIOPATHY
structural injury and loss of functioning nephron unitsChildhood HUS
may account for long-term sequelae of the disease. At 15
Stx-associated HUS. This form, also referred to as di- years of follow-up, Gagnadoux et al found renal sequelae
arrhea associated (D) HUS, is most often due to E. coli in 83% of children with patchy cortical necrosis, one third
O157:H7 infection and, less frequently to the O111:non- of whom were in ESRD, as compared with none of those
motile, O26:HII, and O103:H2 [reviewed in 79]. It is with pure glomerular TMA) [82]. Regardless of the renal
characterized by prodromal diarrhea followed by acute damage, however, in the long term, 10 to 42% of children
renal failure. The overall incidence is estimated to be have some renal sequelae (such as proteinuria and/or mod-
2.1 cases per 100,000 persons/year with a peak incidence erate hypertension or mildly reduced GFR), 10 to 22%
in children younger than five years of age (6.1/100,000/ have chronic renal failure, and 2 to 9% ESRD) [81, 82].
year) and the lowest rate in adults 50 to 59 years old Neuraminidase-associated HUS. This is a rare but po-
(0.5/100,000/year) [79]. tentially fatal disease that may complicate pneumonia,
E. coli O157 infection is most common in the warm or less frequently, meningitis caused by Streptococcus
summer months. The average interval between Stx-E. coli pneumoniae [35, 36]. The clinical picture is usually severe,
exposure and illness is three (range of 1 to 8) days [17]. with respiratory distress, anuria, neurological involve-
Illness typically begins with abdominal cramps and non- ment, and coma.
bloody diarrhea; diarrhea may become hemorrhagic in Idiopathic or atypical HUS. This is a subgroup with
70% of cases usually within one or two days. Vomiting unknown etiology and no seasonal pattern that differs
occurs in 30 to 60% of cases and fever in only 30%. from Stx-associated HUS on epidemiologic, clinical, lab-
Serum leukocyte count is usually elevated, and a barium oratory, and prognostic grounds. The onset is usually insid-
enema may demonstrate “thumb-printing,” suggestive ious, without antecedent diarrhea, and may be preceded
of edema and submucosal hemorrhage, especially in the by nephrotic syndrome. The disease occasionally is famil-
region of the ascending and transverse colon. Superficial ial, has a tendency to relapse, and carries a worse progno-
ulcerations or pseudomembranes are common. E. coli sis than Stx-associated HUS [83]. Upper respiratory tract
O157 infection is complicated by HUS in 3 to 7% of the infection may trigger the disease in approximately 30%
sporadic cases and up to approximately 20% or more of of cases [83]. The clinical syndrome resembles TTP. One-
the epidemic forms [17]. HUS is usually diagnosed six third of these patients have central nervous system
days after the onset of diarrhea. After HUS infection, involvement at onset, with convulsions and alterations
Stx-E. coli may be shed in the stool for several weeks of consciousness that persist despite correction of hyper-
after the symptoms are resolved, particularly in younger tension and metabolic complications of renal failure. The
children (5 years age) who in one-third of the cases may outcome is severe [83–85].
carry the organism for over 20 days. Use of antimotility
Adult HUS/TTPagents and antibiotics, bloody diarrhea, fever, vomiting,
elevated serum leukocyte count, extremes of age (in STX-associated HUS/TTP. Albeit less frequently than
particular children 5 years old), and female sex have in children, Stx HUS has been reported even in adults,
been associated with an increased risk of HUS following either in epidemics involving elderly people in nursing
Stx-E. coli infection [17]. homes or in sporadic cases [20, 33]. The etiology and
Fifty percent of patients who develop HUS need dial- pathogenesis of childhood and adult Stx HUS are the
ysis, 75% require red blood cell transfusions, and 25% same, but renal and neurological involvement are usually
have neurological signs, including stroke, seizure, and more severe and sequelae more frequent in adults than
coma [17]. Stx-associated HUS is erroneously regarded in children [86]. Indeed, in older patients, a mortality rate
as a benign disease. Indeed, 3 to 5% of children die in close to 90% has been reported, a figure that is at least
the acute phase and a similar percentage develop end- 10- to 20-fold higher than in pediatric series [20, 33, 86].
stage renal disease (ESRD) [80]. Moreover, long-term Acute idiopathic HUS/TTP. The defining clinical fea-
sequelae are common. In a series of 88 children, Fitzpa- tures include thrombocytopenia, microangiopathic he-
trick et al reported long-term renal dysfunction in 39% molytic anemia, neurological and renal abnormalities,
of cases, a residual glomerular filtration rate (GFR)80 and fever. Neurological symptoms usually dominate the
mL/min 173 m2 in 18%, and persistent microalbuminuria clinical picture, but usually subside within 48 hours after
in 31% [81]. In different series, the incidence of ESRD initiation of plasma therapy [7]. Clinical response and
ranged from 3 to 18% [17]. The duration of anuria is a survival are comparable in patients with and without
strong predictor of residual renal dysfunction. Indeed, renal failure [5, 6].
only 4 of 53 children (7.5%) with a duration of anuria Relapsing and frequently relapsing HUS/TTP. Relaps-
ing forms are increasingly reported [87, 88], as moreless than ten 10 days were found to have a residual GFR
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fluffy material in the subendothelium. These changes arepatients than in the past recover from the initial acute
virtually identical and often indistinguishable from theepisode thanks to improved supportive and specific treat-
microvascular lesions of scleroderma and malignant hy-ments. An extremely rare variant of relapsing HUS/TTP,
pertension [2]. In HUS, the microthrombi are confinedalso known as “chronic relapsing” or “frequent relaps-
primarily to the kidneys (Fig. 2), and thus, renal failureing” HUS/TTP, is characterized by frequent episodes,
is the dominant feature. TTP mainly involves the brain,recurring after symptom-free intervals of a predictable
and intravascular thrombi apparently form and disperseduration (1 month in most cases) [89].
repeatedly, producing intermittent neurological signs. In
pediatric patients, particularly in children younger thanFAMILIAL HUS/TTP
two years of age and in most cases of Stx-associated HUS,This form has a heterogeneous pattern of inheritance
a pattern of glomerular injury is prominent (Fig. 2). Leu-and presents as HUS or as TTP in several members of
kocyte infiltrates and thrombi are common during the
a given family. Less frequently, it may present as HUS early phases of the disease and usually resolve over two
in some and as TTP in other members of the same family. or three weeks. Later on, renal biopsies show ectatic glo-
These are cases in which the disease had different clinical merular capillaries, swollen endothelial cells, and some de-
presentations in the same individual, with some episodes gree of necrosis. Patchy cortical necrosis may be seen in
more reminiscent of HUS and others of TTP [67]. De- more severe cases; crescents are uncommon. Predomi-
creased factor H bioavailability and abnormalities in vWF nant arteriolar involvement, with intimal proliferation and
handling may have an important pathogenetic role in hyperplasia, and secondary glomerular ischemia and col-
familial forms (see paragraph “Genetic predisposition”). lapse are frequently found in idiopathic and familial forms
Genetic counseling is important if pregnancies are planned. and in older children (Figs. 3 and 4) [2]. Prognosis is good
The outcome is usually poor with death or chronic renal in cases with predominantly glomerular changes, but is
failure being reported in 50 to 100% of cases [66] and much more severe in those with primarily vascular dam-
post-transplant recurrences in about 50% of cases [90]. age (Fig. 5) or with acute cortical necrosis. Focal segmen-
tal glomerulosclerosis may be a long-term, chronic sequela
of acute HUS (post-HUS chronic nephropathy) and is
LABORATORY FINDINGS usually seen in children with long-lasting hypertension,
Thrombocytopenia and microangiopathic hemolytic proteinuria, and progressively worsening renal function [2].
anemia are the laboratory hallmarks of HUS/TTP. Pure glomerular involvement is uncommon in adults.
Thrombocytopenia is usually severe, with platelet counts Vascular involvement is the predominant finding and is
associated with more severe hypertension, more frequentbelow 60,000/mm3 in most cases. Platelet survival time
neurological involvement, higher risk of renal and neuro-is reduced, reflecting enhanced platelet disruption in the
logical sequelae, and higher mortality [92]. For instance,circulation. Giant platelets may be seen in the peripheral
in 20 consecutive patients, Morel-Maroger reported onlysmear, a finding consistent with secondary activation of
two cases with almost pure glomerular involvement whothrombocytopoiesis.
completely recovered [92]. None of the remaining 18Anemia is usually severe, hemoglobin levels less than
patients in her series recovered. Ten died, four pro-10 mg/dL being reported in 99% of cases and less than
gressed to ESRD, and four had residual chronic renal6.5 mg/dL in 40% of cases. Serum lactate dehydrogenase
insufficiency and hypertension.(LDH) levels are increased, often at very high levels,
reflecting not only hemolysis, but also diffuse tissue isch- TREATMENT GUIDELINES
emia [91]. Hyperbilirubinemia (mainly unconjugated),
Childhood Stx-E. coli–associated HUS usually recov-reticulocytosis, circulating free hemoglobin, and low or
ers spontaneously and does not require plasma therapyundetectable haptoglobin levels are additional aspecific
[7]. In contrast, a general consensus has been achievedindicators of the accelerated red cell disruption and pro-
that plasma exchange or infusion should always be triedduction. Indeed, detection of fragmented red blood cells
in adult HUS/TTP to minimize the risk of death or long-(schistocytes) with the typical aspect of burr or helmet
term sequelae (Table 1) [7]. The outcome of secondarycells in the peripheral smear together with a negative
forms, instead, mainly depends on the prognosis of theCoombs test (with the exception of streptococcus pneu-
underlying condition. Platelet count and serum LDH aremoniae-associated HUS [35, 36]) are needed to confirm
the most sensitive markers for monitoring the responsethe microangiopathic nature of the hemolysis.
to plasma therapy. Treatment should be continued until
PATHOLOGY complete disease remission is achieved [7]. However,
no clinical parameter predicts the duration for plasmaThe characteristic histologic lesion of HUS and TTP
therapy. The decision to stop or continue plasma therapyconsists of vessel wall thickening (capillaries and arteri-
is empirical. Prompt exacerbation of disease activity, prin-oles), with swelling and detachment of the endothelial
cells from the basement membrane and accumulation of cipally manifested by a falling platelet count and requir-
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Fig. 4. Glomerulus from a patient with atypical HUS with predominantFig. 2. Glomerulus from a patient with a form of HUS with predomi-
vascular involvement. Severe ischemic changes have occurred, charac-nant glomerular involvement. Capillary lumina are narrowed or oc-
terized by marked restriction of the glomerular tuft.cluded by erythrocytes and thrombi. Swelling of endothelial cells and
thickening of the capillary wall with double contours have also occurred.
A marked thickening of the glomerular capillary wall occurs with many
double contours.
Fig. 5. A glomerulus and an interlobular artery from a patient with
atypical HUS with severe vascular involvement. Severe ischemic
Fig. 3. Two arterioles in a case of atypical HUS with severe vascular changes have occurred with marked glomerular restriction and concomi-
involvement. The vascular lumen is extremely narrowed due to miointi- tant severe tubular changes. The vascular lumen is almost entirely
mal proliferation and vascular wall thickening. occluded due to extreme thickening of the vascular wall.
ing the resumption of daily plasma therapy, is common from 40 to 50% to the current 3 to 5%—probably as the
result of better supportive management of anemia, renalafter treatment discontinuation with reported frequen-
cies of 29 to 82% [5, 7, 93]. Of course, this mandates failure, hypertension, and electrolyte and water imbal-
ance [79]. However, no specific therapy aimed to preventadditional treatment. Actually, discontinuation of plasma
therapy is the only way to know whether a durable remis- or limit the microangiopathic process has been proven to
affect the course of the disease in children. Antimotilitysion has been achieved, and many cycles of stopping and
resuming plasma therapy may be required. agents may increase the risk of toxic megacolon. Antibi-
otics given to treat infection due to Stx–producing E.
coli O157:H7 have been found to increase the risk of
CHILDHOOD HUS
overt HUS by 17-fold [94]. Indeed, antibiotic-induced
STX-associated HUS injury to the bacterial membrane might favor the acute
release of large amounts of preformed toxin. Alterna-In typical Stx-associated HUS in children, the mortality
rate has significantly decreased over the last 40 years— tively, antibiotic therapy might give E. coli O157:H7 a
Ruggenenti et al: TMA, HUS and TTP842
T
ab
le
1.
Sp
ec
if
ic
tr
ea
tm
en
ts
of
th
ro
m
bo
ti
c
m
ic
ro
an
gi
op
at
hy
:D
os
es
,m
od
al
it
ie
s
of
ad
m
in
is
tr
at
io
in
,i
nd
ic
at
io
ns
an
d
co
nt
ra
in
di
ca
ti
on
s
T
re
at
m
en
t
A
dm
in
is
tr
at
io
n
In
di
ca
ti
on
-c
om
m
en
t
T
re
at
m
en
ts
of
pr
ov
en
ef
fi
ca
cy
P
la
sm
a
ex
ch
an
ge
1–
2
pl
as
m
a
vo
l/d
ay
F
ir
st
-l
in
e
th
er
ap
y
in
ad
ul
t
an
d
at
yp
ic
al
fo
rm
s;
lif
e
sa
vi
ng
in
ca
se
s
w
it
h
ne
ur
ol
og
ic
al
in
vo
lv
em
en
t;
m
ay
fa
vo
r
re
na
l
fu
nc
ti
on
re
co
ve
ry
;n
o
ri
sk
of
fl
ui
d
ov
er
lo
ad
ev
en
in
pa
ti
en
ts
w
it
h
se
ve
re
ca
rd
ia
c
or
re
na
l
dy
sf
un
ct
io
n
P
la
sm
a
in
fu
si
on
30
–4
0
m
L
/k
g
on
da
y
1,
th
en
F
ir
st
-l
in
e
th
er
ap
y
w
he
n
ex
ch
an
ge
is
no
t
av
ai
la
bl
e;
ef
fe
ct
iv
e
in
th
e
tr
ea
tm
en
t
or
pr
ev
en
-
10
–2
0
m
L
/k
g/
da
y
ti
on
of
re
cu
rr
en
t
ep
is
od
es
P
la
sm
a
cr
yo
su
pe
rn
at
an
t
Se
e
pl
as
m
a
in
fu
si
on
/e
xc
ha
ng
e
Se
co
nd
-l
in
e
th
er
ap
y;
m
ay
be
ef
fe
ct
iv
e
in
ca
se
s
w
ho
do
no
t
re
sp
on
d
to
w
ho
le
pl
as
m
a
in
fu
si
on
/e
xc
ha
ng
e
So
lv
en
t
de
te
rg
en
t-
tr
ea
te
d
pl
as
m
a
Se
e
pl
as
m
a
in
fu
si
on
/e
xc
ha
ng
e
Sa
m
e
in
di
ca
ti
on
s
of
pl
as
m
a
in
fu
si
on
/e
xc
ha
ng
e;
m
ay
lim
it
th
e
ri
sk
of
vi
ra
lc
on
ta
m
in
at
io
n
R
es
cu
e
tr
ea
tm
en
ts
B
ila
te
ra
l
ne
ph
re
ct
om
y
M
ay
be
lif
e
sa
vi
ng
in
ca
se
s
w
it
h
re
fr
ac
to
ry
hy
pe
rt
en
si
on
/t
hr
om
bo
cy
to
pe
ni
a
an
d
hy
pe
r-
te
ns
iv
e
en
ce
ph
al
op
at
hy
;t
o
be
re
st
ri
ct
ed
to
pa
ti
en
ts
w
it
h
bi
op
sy
ev
id
en
ce
of
se
ve
re
re
na
l
va
sc
ul
ar
in
vo
lv
em
en
t
Sp
le
ne
ct
om
y
M
ay
be
ef
fe
ct
iv
e
in
re
la
ps
in
g
fo
rm
s;
to
be
re
st
ri
ct
ed
to
pa
ti
en
ts
w
it
h
fr
eq
ue
nt
re
la
ps
es
an
d
re
qu
ir
in
g
la
rg
e
am
ou
nt
s
of
pl
as
m
a
O
th
er
tr
ea
tm
en
ts
P
re
dn
is
on
e
O
ra
l,
60
–2
00
m
g/
da
y,
ta
pe
re
d
by
5
m
g/
w
ee
k
P
os
si
bl
y
ef
fe
ct
iv
e
in
m
ild
,a
du
lt
fo
rm
s;
ad
di
ti
on
al
th
er
ap
y
in
po
or
re
sp
on
de
rs
to
pl
as
m
a
in
fu
si
on
/e
xc
ha
ng
e
(?
)
G
am
m
a
gl
ob
ul
in
s
In
tr
av
en
ou
s
40
0
m
g/
kg
/d
ay
U
np
ro
ve
n
ef
fi
ca
cy
V
in
cr
is
ti
ne
1.
4
m
g/
m
2
IV
on
da
y
1,
th
an
1
m
g
ev
er
y
4
da
ys
up
to
4
do
se
s
U
np
ro
ve
n
ef
fi
ci
ac
y;
m
ig
ht
de
cr
ea
se
th
e
ri
sk
of
re
cu
rr
en
ce
s
A
nt
it
hr
om
bo
ti
c
ag
en
ts
(h
ep
ar
in
,s
tr
ep
to
ki
na
se
)
In
tr
av
en
ou
s
U
np
ro
ve
n
ef
fi
ca
cy
;i
nc
re
as
ed
ri
sk
of
bl
ee
di
ng
A
nt
ip
la
te
le
t
ag
en
ts
(a
sp
ir
in
,p
ro
st
ac
yc
lin
)
O
ra
l
or
in
tr
av
en
ou
s
U
np
ro
ve
n
ef
fi
ca
cy
;i
nc
re
as
ed
ri
sk
of
bl
ee
di
ng
V
it
am
in
E
O
ra
l,
10
00
m
g/
m
2 /d
ay
P
ro
ba
bl
y
ef
fe
ct
iv
e
in
St
x-
as
so
ci
at
ed
H
U
S;
to
be
te
st
ed
in
co
nt
ro
lle
d
tr
ia
ls
T
re
at
m
en
ts
un
de
r
in
ve
st
ig
at
io
n
Sy
ns
or
b-
P
K
O
ra
l,
0.
5
g
pe
r
kg
bo
dy
w
ei
gh
t,

7
da
ys
;
M
ay
pr
ev
en
t/
lim
it
Sh
ig
a
to
xi
n
ab
so
rp
ti
on
an
d
th
e
ri
sk
of
fu
ll-
bl
ow
n
St
x-
as
so
ci
at
ed
H
U
S;
to
be
ad
m
in
is
te
re
d
at
th
e
on
se
t
of
un
de
r
cl
in
ic
al
in
ve
st
ig
at
io
n.
di
ar
rh
ea
or
w
he
n
in
ge
st
io
n
of
co
nt
am
in
at
ed
fo
od
is
su
sp
ec
te
d
Ruggenenti et al: TMA, HUS and TTP 843
selective advantage if these organisms are not as readily plasma infusion or exchange, occasionally in combina-
tion with steroids, has been associated with recovery.eliminated from the bowel as are the normal intestinal
Idiopathic/atypical HUS. Plasma therapy is usually rec-flora. Moreover, several antimicrobial drugs, particularly
ommended in these forms, although they have an almostthe quinolones, trimethoprim, and furazolidone, are po-
invariably poor outcome despite the therapy.tent inducers of the expression of the Stx 2 gene and may
increase the level of toxin in the intestine [95]. However,
ADULT HUS/TTPthese considerations do not necessarily apply to many cases
STX-associated HUS/TTP. The evaluation of treat-of bloody diarrhea, in particular in South America and
ment efficacy in adult patients is difficult because mostIndia, which are precipitated by E. coli strains different
of the information is derived by uncontrolled series,from O157:H7 or by other bacteria, such as S. dysenteriae
which may include also non-Stx-HUS cases [86]. In par-type 1 [96]. For instance, when hemorrhagic colitis is caused
ticular, no prospective, randomized trials are available toby S. dysenteriae type 1, early and empirical antibiotic
definitely establish whether plasma infusion or exchangetreatment shortens the duration of diarrhea, decreases
may offer some specific benefit as compared to support-the incidence of complications, and reduces the risk of
ive treatment alone. However, comparative analyses oftransmission by shortening the duration of bacterial shed-
two large series of patients treated [33] or not [20] withding [97]. Thus, in developing countries where Shigella is
plasma suggest that plasma therapy may dramaticallythe most frequent cause of hemorrhagic colitis, antibiotic
decrease overall mortality of Stx-E. coli O157:H7-associ-therapy should be started early and even before the in-
ated HUS. These findings lead others and us to considervolved pathogen is identified [96].
plasma infusion or exchange indicated in adult patients,New agents targeted to prevent organ exposition to
in particular in those with severe renal insufficiency andStx are currently under evaluation. The most promising
central nervous system involvement [6, 7].are Synsorb-PK, a resin composed of repeated synthetic
Acute idiopathic HUS/TTP. Plasma manipulation is acarbohydrate determinants linked to colloidal silica that
cornerstone in the therapy of acute idiopathic HUS/TTP.binds Stx; recombinant modified E. coli that displays a
Exchange has been claimed to be superior than to plasmaStx receptor mimic on its surface and adsorbs and neutral-
infusion in one study [5]. However, patients treated withizes Stx with very high efficiency; and “STARFISH,” an
exchange were given larger amounts of plasma than thoseoligovalent, water-soluble carbohydrate ligand that can
treated with plasma infusion alone. Indeed, when equiva-simultaneously engage all five B subunits of two toxin
lent volumes of plasma were given, infusion and exchangemolecules. These approaches offer potent new weapons
appeared to be equally effective [100]. Plasma exchangeagainst Stx-E. coli–induced hemorrhagic diarrhea and
should be considered as first-choice therapy when renal
HUS. Oral administration of Synsorb or recombinant
insufficiency or heart failure limit the amount of plasma
modified E. coli could efficiently clear toxin from the that can be provided with infusion alone. Cryosuperna-
gut, whereas intravenous administration of “STARFISH” tant fraction (that is, plasma from which a cryoprecypi-
might help to prevent toxin that already has entered the tate containing the largest plasma vWF multimers, fibrin-
circulation from destroying kidney function and micro- ogen, and fibronectin has been removed) instead of fresh
vessels. Preliminary analyses of an ongoing trial in Can- frozen plasma has been successful in treating a small
ada found that early treatment (within two days after number of patients who did not respond to repeated ex-
the onset of diarrhea) with Synsorb-PK decreased the changes or infusions with fresh frozen plasma [101]. The
risk of HUS from 17 to 7% [98]. Toxin-neutralizing anti- rationale for this approach is that plasma cryosuperna-
bodies might be a future possible prevention for E. coli tant may provide the same beneficial factor(s) found in
infection. Actually, natural infection with E. coli O157 whole plasma, but does not contain those factors (includ-
does not confer immunity, and no human vaccine is cur- ing large vWF multimers) that may actually sustain the
rently available. Nevertheless, Shiga toxoid vaccines have microangiopathic process until remission is achieved. On
been shown to be effective in preventing related diseases the basis of the previously mentioned information, the
in animals. Generalized pasteurization of ground beef use of plasma cryosupernatant has been suggested as first
through irradiation will further help to limit/prevent E. line therapy of adult HUS/TTP. However, results of the
coli O157 and other food-borne pathogen infections. few small, randomized studies failed to find differences
Neuroaminidase-associated HUS. The role of plasma between the two products.
therapy is controversial. In theory, whole blood and Usually one plasma volume (40 mL/kg) is exchanged
plasma should be avoided, since they contain IgM and per session. Treatment can be intensified by increasing
may accelerate polyagglutination and hemolysis through the volume of plasma replaced. The twice-daily exchanges
IgM-mediated erythrocyte and endothelial cell injury of one plasma volume is probably the treatment of choice
[99]. Thus, patients should be treated only with antibiot- for refractory patients in order to minimize the recycling
of infused plasma [7]. Serum LDH and platelet countics and washed red cells [36]. In some cases, however,
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are the most reliable markers of response, and plasma recover with delivery, and plasma therapy should be
therapy should be continued until they are persistently restricted only to cases at imminent risk of death or with
normalized. Occasional patients with idiopathic HUS/ no evidence of disease recovery over 24 to 48 hours after
TTP do not achieve remission despite plasma therapy. delivery [103]. Cases occurring earlier in the course of
Some of them become plasma-dependent and require gestation are usually episodes of acute, idiopathic HUS/
continued treatment, since disease relapses as soon as TTP and are best treated with plasma therapy. Those
plasma infusion or exchange is stopped. Splenectomy occurring after a normal delivery are usually defined as
has been found to induce remission in some plasma- postpartum HUS. The pathogenesis is unclear, and the
resistant cases, but was ineffective and actually increased outcome is usually poor with a high incidence of renal
morbidity and mortality in others [93]. Recently, the sequelae even despite aggressive plasma therapy. Cases
presence in the circulation of autoantibodies against recurring after a kidney transplant are almost invariably
vWF-cleaving protease has been claimed to help identify found in the context of a familial or recurrent background
patients who may benefit of glucocorticoid or vincristine and are usually associated with a poor outcome [90].
treatment, removal of IgG by immunoadsorption on pro- Quite different is the outcome of de novo post-transplant
tein A, or splenectomy [51]. HUS that may be associated with CsA or tacrolimus
Consistent data are available on the beneficial effect therapy or with vascular rejection. Removal of the drug
of bilateral nephrectomy, in particular in patients with and effective treatment of the rejection, plus plasma
severe renal involvement, refractory hypertension, and therapy, can cure the disease.
signs of hypertensive encephalopathy [62]. Combined to
plasma therapy, antiplatelet agents have no additional ACKNOWLEDGMENTS
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